Short answers, pulled from the story.
DSM-5 defines three presentations of ADHD: predominantly inattentive (ADHD-PI), predominantly hyperactive-impulsive (ADHD-HI), and combined presentation (ADHD-C). To receive a diagnosis, a child under 17 must show at least six symptoms from the relevant category for six months or more across at least two settings, while adults and those 17 and older require at least five symptoms.
ADHD has a heritability rate of 70 to 80 percent, meaning the majority of its presence in the population traces to genetic factors. It is polygenic, involving many gene variants each contributing a small effect; key genes include DAT, DRD4, DRD5, TAAR1, MAOA, COMT, DBH, SNAP25, and BDNF. A common variant of the gene latrophilin 3 is estimated to account for about 9 percent of cases.
Hyperfocus is a state of intense, narrow concentration on a specific task or stimulus for a prolonged period, commonly reported in people with ADHD. It is not a formally recognized symptom in diagnostic manuals such as DSM-5, but studies published in 2016, 2019, and 2024 found that individuals with ADHD experience it more often or more acutely. It is linked to risks including internet addiction and certain types of offending behaviour.
According to data collected in 2022 by the U.S. Centers for Disease Control and Prevention, nearly 78 percent of children with ADHD have at least one co-occurring condition. Common comorbidities include autism spectrum disorder (21 percent), learning disabilities (20 to 30 percent), oppositional defiant disorder (up to 50 percent in combined-presentation cases), and anxiety and mood disorders.
Methylphenidate and amphetamine or its derivatives are the most common first-line treatments for ADHD. About 70 percent of people respond to the first stimulant tried, with as few as 10 percent responding to neither amphetamines nor methylphenidate. Non-stimulant options approved by the FDA include atomoxetine and viloxazine. Since at least September 2021, there is a unanimous global scientific consensus that methylphenidate is safe and highly effective.
Systematic reviews in 2017 and 2020 found strong evidence that ADHD is associated with increased suicide risk across all age groups. A 2019 meta-analysis found that the prevalence of suicide attempts in individuals with ADHD was 18.9 percent, compared to 9.3 percent in individuals without ADHD. Potential drivers include functional impairment, negative educational and occupational outcomes, and financial distress, though the precise causal pathway remains unclear due to complicating comorbid conditions.